↓ Skip to main content

Anti-fibrotic Potential of AT2 Receptor Agonists

Overview of attention for article published in Frontiers in Pharmacology, August 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
1 news outlet
twitter
4 X users
patent
1 patent

Readers on

mendeley
52 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anti-fibrotic Potential of AT2 Receptor Agonists
Published in
Frontiers in Pharmacology, August 2017
DOI 10.3389/fphar.2017.00564
Pubmed ID
Authors

Yan Wang, Mark Del Borgo, Huey W. Lee, Dhaniel Baraldi, Baydaa Hirmiz, Tracey A. Gaspari, Kate M. Denton, Marie-Isabel Aguilar, Chrishan S. Samuel, Robert E. Widdop

Abstract

There are a number of therapeutic targets to treat organ fibrosis that are under investigation in preclinical models. There is increasing evidence that stimulation of the angiotensin II type 2 receptor (AT2R) is a novel anti-fibrotic strategy and we have reviewed the published in vivo preclinical data relating to the effects of compound 21 (C21), which is the only nonpeptide AT2R agonist that is currently available for use in chronic preclinical studies. In particular, the differential influence of AT2R on extracellular matrix status in various preclinical fibrotic models is discussed. Collectively, these studies demonstrate that pharmacological AT2R stimulation using C21 decreases organ fibrosis, which has been most studied in the setting of cardiovascular and renal disease. In addition, AT2R-mediated anti-inflammatory effects may contribute to the beneficial AT2R-mediated anti-fibrotic effects seen in preclinical models.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 52 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 17%
Student > Ph. D. Student 8 15%
Student > Bachelor 6 12%
Researcher 4 8%
Other 2 4%
Other 5 10%
Unknown 18 35%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 7 13%
Medicine and Dentistry 7 13%
Agricultural and Biological Sciences 6 12%
Pharmacology, Toxicology and Pharmaceutical Science 5 10%
Unspecified 2 4%
Other 4 8%
Unknown 21 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 April 2021.
All research outputs
#3,174,320
of 25,732,188 outputs
Outputs from Frontiers in Pharmacology
#1,387
of 19,996 outputs
Outputs of similar age
#54,913
of 324,916 outputs
Outputs of similar age from Frontiers in Pharmacology
#19
of 262 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 19,996 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,916 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 262 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.